During the conference call a clinical update will take place. I hope that we get a good shot in the arm with some good news. Maybe some news will come out after hours today or premarket in the morning. Good luck longs....hanging in there!
"The safety profile of adenocarcinoma patients treated with the combination of ganetespib (G) and docetaxel (D) was favorable, consistent with previously reported results. The most common adverse events (AEs), all grades, were neutropenia (46% vs. 45%), diarrhea (50% vs. 17%) and fatigue (35% vs. 24%), for G+D (N=123) vs. D (N=126), respectively. Diarrhea was effectively prevented or managed with standard supportive care; the incidence of grade 3 or 4 diarrhea was 4% (G+D) vs. 0 (D). Fatigue was predominantly grade 1 and grade 2; grade 3 or 4 fatigue was 6% (G+D) vs. 4% (D). The most common grade 3 or 4 AEs were neutropenia (41% vs. 42%), febrile neutropenia (9% vs. 5%), and leukopenia (10% vs. 6%). Only one case of visual impairment was reported in this study, which was mild (Grade 1) and transient. The safety profile of patients in the chemosensitive population being evaluated in Phase 3 was comparable to the profile in the adenocarcinoma population.
"Results from the final analysis of GALAXY-1 support our selection of the chemosensitive patient population for study in the pivotal Phase 3 GALAXY-2 trial," said Dr. Vojo Vukovic, Chief Medical Officer, Synta. "This mature data set confirms that the improvements in progression-free survival and overall survival with ganetespib and docetaxel in chemosensitive patients are very encouraging."
Publication of the final data from GALAXY-1 is expected in the second half of 2014. A slide set summarizing these results can be found on the Synta website. These slides will be referred to during the Company's first quarter 2014 results conference call at 10:00 AM (ET) this morning.
Ganetespib, an investigational drug candidate, is a selective inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone which controls the folding and activation of a number of client proteins that drive tumor development and progression. Many solid and hematologic tumors are dependent on Hsp90 client proteins including pro
other than a summary for the newbies, i dont expect anything newsworthy from a clinical standpoint. usually there's a news release on individual developments. please correct me if I'm wrong. nevertheless the bbs are close together and conditions are ripe for a movement one way or another out of the recent narrow trading range.